Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.


Current relapse rates in acute myeloid leukemia (AML) highlight the need for new therapeutic strategies. Panobinostat, a novel pan-histone deacetylase inhibitor, and marizomib, a second-generation proteasome inhibitor, are emerging as valuable therapeutic options for hematological malignancies. Here we evaluated apoptotic effects of this combinatorial… (More)
DOI: 10.1016/j.leukres.2014.12.014


  • Presentations referencing similar topics